2012
Contribution of Endogenous Bradykinin to Fibrinolysis, Inflammation, and Blood Product Transfusion Following Cardiac Surgery: A Randomized Clinical Trial
Balaguer JM, Yu C, Byrne JG, Ball SK, Petracek MR, Brown NJ, Pretorius M. Contribution of Endogenous Bradykinin to Fibrinolysis, Inflammation, and Blood Product Transfusion Following Cardiac Surgery: A Randomized Clinical Trial. Clinical Pharmacology & Therapeutics 2012, 93: 326-334. PMID: 23361105, PMCID: PMC4031681, DOI: 10.1038/clpt.2012.249.Peer-Reviewed Original ResearchConceptsBradykinin B2 receptor antagonismB2 receptor antagonismCardiopulmonary bypassEndogenous bradykininTissue-type plasminogen activatorHoe 140Receptor antagonismBradykinin B2 receptor antagonistSubsequent transfusion requirementsBlood product transfusionProportion of patientsB2 receptor antagonistD-dimer concentrationD-dimer formationEACA treatmentTransfusion requirementsPostoperative bleedingProduct transfusionBlood lossCardiac surgeryInflammatory cytokinesReceptor antagonistClinical trialsFibrinolytic capacityInflammatory response
2002
Improving Medication Use in Newly Admitted Home Healthcare Patients: A Randomized Controlled Trial
Meredith S, Feldman P, Frey D, Giammarco L, Hall K, Arnold K, Brown NJ, Ray WA. Improving Medication Use in Newly Admitted Home Healthcare Patients: A Randomized Controlled Trial. Journal Of The American Geriatrics Society 2002, 50: 1484-1491. PMID: 12383144, DOI: 10.1046/j.1532-5415.2002.50402.x.Peer-Reviewed Original ResearchConceptsHome health agenciesMedication useNonsteroidal antiinflammatory drugsMedication problemsHome care nursesTherapeutic duplicationUsual careIntervention patientsControl patientsHealth agenciesIntervention effectsPeptic ulcer complicationsProportion of patientsHome healthcare patientsLarge home health agencyHome health careAdverse intervention effectsUlcer complicationsCardiovascular medicationsQualifying patientsControlled TrialsAdrenergic effectsClinical pharmacistsNurse visitsTrial endpoints